Landscape of <i>BCL2</i> Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

Landscape of <i>BCL2</i> Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, wi...

Full description

Bibliographic Details
Main Authors: Lili Kotmayer, Tamás László, Gábor Mikala, Richárd Kiss, Luca Lévay, Lajos László Hegyi, Stefánia Gróf, Tibor Nagy, Gábor Barna, Péter Farkas, Júlia Weisinger, Zsolt Nagy, Alexandra Balogh, Tamás Masszi, Judit Demeter, Adrienn Sulák, Zoltán Kohl, Hussain Alizadeh, Miklós Egyed, Piroska Pettendi, Lajos Gergely, Márk Plander, Zsolt Pauker, András Masszi, András Matolcsy, Róbert Szász, Csaba Bödör, Donát Alpár
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:International Journal of Molecular Sciences
Subjects:
CLL
venetoclax
BCL2
therapy resistance
molecular monitoring
Online Access:https://www.mdpi.com/1422-0067/24/6/5802

Internet

https://www.mdpi.com/1422-0067/24/6/5802

Similar Items